- What is the role of the immunotherapy in the neoadjuvant setting?
- Is efficacy of immunotherapy influenced by the association with cytotoxic agents? - Which agents (anthracyclins, platin or taxanes)?
- Do cisplatin-ineligible patients benefit from an immunotherapy approach?
- Is there any predictive biomarker for chemotherapy and/or immunotherapy?
Clinical trial information: 2017-002758-35.
Presented by: Nieves Martinez Chanza, MD, Jules Bordet Institut and Erasme Hospital, Brussels, Belgium
Co-Authors: Thierry Andre Roumeguere, Spyridon Sideris, Thierry Gil, Alexandre Peltier, Ahmad Awada
Written By: Zachary Klaassen, MD, Urologic Oncology Fellow, University of Toronto, Princess Margaret Cancer Centre, @zklaassen_md at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, February 8-10, 2018 - San Francisco, CA
References:
1. Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, phase Ib study. J Clin Oncol 2017;35(19):2117-2124.